Amgen Buying Into Risky New Cholesterol Drug Class

By | September 16, 2015

Scalper1 News

Big biotech Amgen (AMGN) agreed to pay up to $1.55 billion for a Dutch biotech developing a new cholesterol drug, the company said Wednesday. Amgen will pay $300 million upfront for privately held Dezima, which has a midstage drug candidate called TA-8995 for lowering LDL cholesterol. If the drug succeeds, Amgen is on the hook for up to $1.25 billion in milestone payments. It will also pay an unspecified royalty to Mitsubishi Tanabe Pharma, from Scalper1 News

Scalper1 News